Literature DB >> 22012037

Ischemia-modified albumin in type 2 diabetic patients with and without peripheral arterial disease.

Shao-gang Ma1, Chun-ling Wei, Bing Hong, Wei-nan Yu.   

Abstract

OBJECTIVE: To determine whether there is an association between serum ischemia-modified albumin and the risk factor profile in type 2 diabetic patients with peripheral arterial disease and to identify the risk markers for peripheral arterial disease.
METHODS: Participants included 290 patients (35.2% women) with type 2 diabetes. The ankle-brachial pressure index was measured using a standard protocol, and peripheral arterial disease was defined as an ankle-brachial index <0.90 or >1.3. The basal ischemia-modified albumin levels and clinical parameters were measured and analyzed. The risk factors for peripheral arterial disease were examined by multiple logistic analyses.
RESULTS: Age, systolic blood pressure, total cholesterol, low-density lipoprotein cholesterol, urine albumin, homocysteine, and ischemia-modified albumin were significantly higher in patients with peripheral arterial disease than in disease-free patients (p<0.05), while ankle-brachial index was lower in the former group (p<0.05). Ischemia-modified albumin was positively associated with HbA1c and homocysteine levels (r = 0.220, p = 0.030; r = 0.446, p = 0.044, respectively), while no correlation was found with ankle-brachial index. Multiple logistic analyses indicated that HbA1c, systolic blood pressure, homocysteine and ischemia-modified albumin were independent risk factors for peripheral arterial disease in the diabetic subjects.
CONCLUSION: The baseline ischemia-modified albumin levels were significantly higher and positively associated with HbA1c and homocysteine levels in type 2 diabetic patients with peripheral arterial disease. Ischemia-modified albumin was a risk marker for peripheral arterial disease. Taken together, these results might be helpful for monitoring diabetic peripheral arterial disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22012037      PMCID: PMC3180151          DOI: 10.1590/s1807-59322011001000003

Source DB:  PubMed          Journal:  Clinics (Sao Paulo)        ISSN: 1807-5932            Impact factor:   2.365


  24 in total

1.  Detection of peripheral vascular stenosis by assessing skeletal muscle flow reserve.

Authors:  Thanjuvar Bragadeesh; Ibrahim Sari; Marco Pascotto; Antonio Micari; Sanjiv Kaul; Jonathan R Lindner
Journal:  J Am Coll Cardiol       Date:  2005-03-01       Impact factor: 24.094

2.  Ischemia-modified albumin levels predict long-term outcome in patients with acute myocardial infarction. The French Nationwide OPERA study.

Authors:  Eric Van Belle; Jean Dallongeville; Eric Vicaut; Alexia Degrandsart; Cathrine Baulac; Gilles Montalescot
Journal:  Am Heart J       Date:  2010-04       Impact factor: 4.749

3.  Association of glucose metabolism, smoking and cardiovascular risk factors with incident peripheral arterial disease: the DESIR study.

Authors:  Robyn J Tapp; Beverley Balkau; Jonathan E Shaw; Paul Valensi; Martine Cailleau; Eveline Eschwege
Journal:  Atherosclerosis       Date:  2006-05-03       Impact factor: 5.162

Review 4.  Medical treatment of peripheral arterial disease.

Authors:  Graeme J Hankey; Paul E Norman; John W Eikelboom
Journal:  JAMA       Date:  2006-02-01       Impact factor: 56.272

5.  Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus.

Authors:  Michelle Kaefer; Sílvia J Piva; José A M De Carvalho; Dievan B Da Silva; Aline M Becker; Adriane C Coelho; Marta M M F Duarte; Rafael N Moresco
Journal:  Clin Biochem       Date:  2009-12-05       Impact factor: 3.281

6.  A novel indicator of widespread endothelial damage and ischemia in diabetic patients: ischemia-modified albumin.

Authors:  Kubilay Ukinc; Selcuk Eminagaoglu; Halil Onder Ersoz; Cihangir Erem; Caner Karahan; Arif Bayram Hacihasanoglu; Mustafa Kocak
Journal:  Endocrine       Date:  2009-09-26       Impact factor: 3.633

7.  Are elevated homocysteine plasma levels related to peripheral arterial disease? Results from a cross-sectional study of 6880 primary care patients.

Authors:  H Darius; D Pittrow; R Haberl; H J Trampisch; A Schuster; S Lange; H G Tepohl; J R Allenberg; C Diehm
Journal:  Eur J Clin Invest       Date:  2003-09       Impact factor: 4.686

8.  Biomarkers of inflammation and thrombosis as predictors of near-term mortality in patients with peripheral arterial disease: a cohort study.

Authors:  Himabindu Vidula; Lu Tian; Kiang Liu; Michael H Criqui; Luigi Ferrucci; William H Pearce; Philip Greenland; David Green; Jin Tan; Daniel B Garside; Jack Guralnik; Paul M Ridker; Nader Rifai; Mary M McDermott
Journal:  Ann Intern Med       Date:  2008-01-15       Impact factor: 25.391

9.  Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study.

Authors:  W R Hiatt; S Hoag; R F Hamman
Journal:  Circulation       Date:  1995-03-01       Impact factor: 29.690

10.  Ischemia-modified albumin level in type 2 diabetes mellitus - Preliminary report.

Authors:  Agnieszka Piwowar; Maria Knapik-Kordecka; Maria Warwas
Journal:  Dis Markers       Date:  2008       Impact factor: 3.434

View more
  18 in total

1.  Increased Oxidatively Modified Forms of Albumin in Association with Decreased Total Antioxidant Activity in Different Types of Hypertensive Disorders of Pregnancy.

Authors:  Jyothi M P D'souza; Sindhu Harish; Vinitha Ramanath Pai; Chitra Shriyan
Journal:  Indian J Clin Biochem       Date:  2016-06-07

2.  Increased serum levels of ischemia-modified albumin and C-reactive protein in type 1 diabetes patients with ketoacidosis.

Authors:  Shao-gang Ma; Yue Jin; Wei Xu; Wen Hu; Feng Bai; Xiao-juan Wu
Journal:  Endocrine       Date:  2012-03-23       Impact factor: 3.633

3.  Ischemia-modified albumin levels in overt and subclinical hypothyroidism.

Authors:  S V Reddy; M M Suchitra; V Pradeep; S Alok; V Suresh; A R Bitla; P V L N Srinivasa Rao
Journal:  J Endocrinol Invest       Date:  2015-04-11       Impact factor: 4.256

4.  Associations of FPG, A1C and disease duration with protein markers of oxidative damage and antioxidative defense in type 2 diabetes and diabetic retinopathy.

Authors:  V S Reddy; P Agrawal; S Sethi; N Gupta; R Garg; H Madaan; V Kumar
Journal:  Eye (Lond)       Date:  2015-09-18       Impact factor: 3.775

5.  Ischemia Modified Albumin (IMA) - A Marker of Glycaemic Control and Vascular Complications in Type 2 Diabetes Mellitus.

Authors:  Rajinder Chawla; Rinchu Loomba; Deepak Guru; Vikas Loomba
Journal:  J Clin Diagn Res       Date:  2016-03-01

6.  Serum ischemic modified albumin levels might not be a marker of oxidative stress in patients with hypothyroidism.

Authors:  Kerem Ersoy; İnan Anaforoğlu; Ekrem Algün
Journal:  Endocrine       Date:  2012-09-23       Impact factor: 3.633

7.  Assessment of Left Ventricular Structural Remodelling in Patients with Diabetic Cardiomyopathy by Cardiovascular Magnetic Resonance.

Authors:  Yongning Shang; Xiaochun Zhang; Liu Chen; Weiling Leng; Xiaotian Lei; Qi Yang; Ziwen Liang; Jian Wang
Journal:  J Diabetes Res       Date:  2016-06-22       Impact factor: 4.011

8.  Does ischemia-modified albumin level predict severity of obstructive sleep apnea?

Authors:  Mustafa Düger; Ekrem Cengiz Seyhan; Mehmet Zeki Günlüoğlu; Mustafa Bolatkale; Mehmet Akif Özgül; Demet Turan; Efsun Uğur; Gözde Ülfer
Journal:  Sleep Breath       Date:  2020-03-25       Impact factor: 2.816

9.  Serum Ischemia-Modified Albumin, Fibrinogen, High Sensitivity C- Reactive Proteins in Type-2 Diabetes Mellitus without Hypertension and Diabetes Mellitus with Hypertension: A Case-Control Study.

Authors:  Sushith Sushith; Herijenahalli Nagaraju Krishnamurthy; Shridhar Reshma; D'Sa Janice; Gopal Madan; Kumar Jeppu Ashok; Mangalore Balakrishna Prathima; Bhuvanesh Sukhlal Kalal
Journal:  Rep Biochem Mol Biol       Date:  2020-07

10.  Influence of obstructive sleep apnea on serum butyrylcholinesterase activity and ischemia-modified albumin levels.

Authors:  Liu-Xue Yang; Shao-Gang Ma; Hong Liu; Wei Xu
Journal:  Clinics (Sao Paulo)       Date:  2013-07       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.